Sanara MedTech Investor Presentation Disclaimers This presentation contains forward-looking statements that discuss expectations as to future trends, plans, events, results of operations or financial condition, or state other information relating to Sanara MedTech Inc. (the "Company," "Sanara," "we," "our" or "us"). All statements other than statements of historical fact contained herein are forward-looking statements. These statements may be identified by terms such as "aims," "anticipates," "believes," "c ...

Acacia Research (ACTG) FY Conference Summary Company Overview - Acacia Research has transitioned from an intellectual property business to a value-based acquirer of companies, focusing on creating a diversified portfolio of assets [2][3] - The company has a book value of approximately $577 million, translating to about $6 per share, with $340 million in cash and public securities [4] Financial Performance - Acacia generated $222 million in revenue and $61 million in EBITDA, with $40 million of EBITDA related to its former intellectual property business [5] - The company operates with no debt, emphasizing a strong financial position [5] Investment Strategy - The management team, led by the CEO with a private equity background, focuses on acquiring undervalued businesses, particularly in contrarian sectors [6][8] - Acacia aims to improve the operational efficiency and profitability of acquired businesses, emphasizing hands-on management rather than passive ownership [10][11] - The company has seen a significant number of acquisition opportunities, evaluating 350 businesses last year and 280 so far this year, but remains selective [9][50] Recent Acquisitions - Acacia has made strategic acquisitions, including Benchmark Energy and Deflecto, to build a scaled oil and gas platform and diversify its portfolio [15][22] - The acquisition of Benchmark was based on identifying dislocation in the oil and gas market, focusing on cash flow generation rather than traditional valuation metrics [17][19] - Deflecto was acquired as a collection of three unrelated businesses, with plans to streamline operations and enhance value through cost-cutting and management alignment [22][24] Operational Focus - The company emphasizes operational improvements and continuous enhancement of acquired businesses, aiming to generate cash flow and increase margins [11][20] - Acacia's approach includes leveraging existing management expertise and operational partners to drive performance in acquired companies [8][26] Market Position and Future Outlook - Acacia is exploring opportunities in specialty lending and insurance, indicating a strategic focus on markets with limited capital flow [51][52] - The company is cautious about entering new markets, preferring to build around existing positions and leverage its team's expertise [54] - Acacia aims to unlock trapped value in its portfolio, with a long-term vision of growing into a formidable public holding company with multiple large businesses [42][43] Conclusion - Acacia Research is positioned as a value-oriented acquirer with a strong financial foundation and a clear strategy for operational improvement and growth through selective acquisitions [34][55]

Core Insights - Hims & Hers Health, Inc. has established itself as a leading direct-to-consumer healthcare platform through a subscription-based revenue model, achieving 2.4 million subscribers as of Q1 2025, a 38.4% year-over-year increase [1][7] - The company reported $576.4 million in online revenue, reflecting a 115.3% year-over-year growth, contributing nearly all of its total revenues of $586 million [1][7] - The Monthly Online Revenue per Average Subscriber increased to $84, a 52.7% rise from $55, indicating deeper customer engagement and upselling of premium services [2] Subscription Model and Customer Engagement - Hims & Hers has a robust pipeline with $110.8 million in deferred revenues as of March 2025, highlighting the strength of its subscription model [2][7] - Recent partnerships with Novo Nordisk and NovoCare Pharmacy have expanded access to GLP-1 weight loss offerings, enhancing the value of the subscription model [3] - The company’s subscription model is designed to provide continuous, personalized care, which is crucial for long-term growth and customer loyalty [3] Industry Comparisons - LifeMD, Inc. reported that 86% of its Q1 2025 revenues came from recurring subscription services, with 291,000 active subscribers, showcasing strong demand [4] - Doximity, Inc. generates over 95% of its revenue from enterprise subscription contracts, with a net revenue retention rate of 119%, indicating strong customer expansion [5] Financial Performance and Valuation - Hims & Hers shares have surged 138.1% year to date, outperforming the industry average gain of 29.7% [6] - The forward 12-month price-to-sales ratio for Hims & Hers is 5X, lower than the industry average of 6.3X but higher than its five-year median of 2.6X [8] - The Zacks Consensus Estimate for Hims & Hers' 2025 earnings per share suggests a 170.4% improvement from 2024 [10]

Let's talk a little bit about today. Lakebase was sort of I thought it was really interesting that makes data more useful for the AI era, but it also brings you onto the home turf of really big tech companies like Oracle and Microsoft and Amazon. What gives you the confidence that you can compete with these guys in their own backyard.Yeah, I mean so basically this technology hasn't changed for 40 years. It's been basically the same and you know it's so locked in. Once you have your data there, you can't mov ...

America’s Car-Mart (CRMT) Q4 2025 Earnings Call June 12, 2025 09:00 AM ET Company Participants Vickie Judy - Chief Accounting OfficerDouglas Campbell - CEO & PresidentJonathan Collins - CFOJamie Fischer - COOKyle Joseph - Managing DirectorJohn Murphy - Managing Director Conference Call Participants Vincent Caintic - MD & Finance Analyst Vickie Judy I'm Vicky Judy, the company's chief accounting officer. Welcome to America's Car Mart's Fourth Quarter Fiscal Year twenty twenty five Earnings Call for the perio ...

Financial Data and Key Metrics Changes - The company reported a net income of $17.9 million for the fiscal year 2025, a significant improvement of over $49 million from a net loss of $31.4 million in the previous year [11] - Gross margin for Q4 increased to 36.4%, up from 35.5% in the prior year, with a full-year gross margin of 36.7%, reflecting a 200 basis point improvement [24][25] - Net charge-offs as a percentage of average finance receivables improved to 6.9% in Q4 from 7.3% in the prior year [27] Business Line Data and Key Metrics Changes - The company sold 57,022 units for the full year, a decrease of 1.7% year-over-year, but Q4 saw a 2.6% increase in unit sales volume [21] - Interest income increased by 4.2% in Q4, contributing to incremental revenue growth despite a decrease in vehicle sales price [21] - The average time to repossession improved by 14% compared to the same period in the prior year, indicating better customer retention [27] Market Data and Key Metrics Changes - The average selling price of vehicles decreased by $316 to $17,240 in Q4, yet the company managed to drive a 1.5% increase in revenue compared to the prior year [21] - The company experienced a tighter supply environment, with procurement costs increasing by approximately $300 per unit due to tariffs [34] Company Strategy and Development Direction - The company is focusing on enhancing its collections infrastructure and has relaunched the "Pay Your Way" platform to provide more flexible payment options for customers [12][13] - A new seven by seven underwriting scorecard has been implemented to improve risk assessment and pricing strategies, which is expected to enhance credit performance [15][19] - The company aims to leverage its balance sheet and integrated sales and financing model to capture additional market share and drive future growth [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the dynamic used car market and emphasized the importance of diversifying underwriting to expand the asset base [34][35] - The leadership team acknowledged the ongoing challenges posed by a tighter supply environment but remains optimistic about the company's strategic initiatives and growth opportunities [36] Other Important Information - The company successfully closed a term securitization, issuing $216 million in asset-backed notes with a weighted average coupon of 6.27%, reflecting improved investor confidence [9] - SG&A expenses increased by 8.6% due to investments in technology and talent, but the company achieved a 6.1% increase in SG&A per customer, indicating improved cost efficiency [31] Q&A Session Summary Question: Impact of macroeconomic factors on business - Management noted that the speculative nature of the wholesale environment began affecting pricing towards the end of the quarter, but overall sales growth is seen as sustainable rather than a pull forward from tax season [40][41] Question: Updates on operational upgrades and partnerships - Management highlighted that gross profit margins have improved, and they are optimistic about the ongoing partnership with Cox Automotive to enhance operational efficiency [46][47] Question: Effects of risk-based pricing on P&L - The rollout of risk-based pricing is expected to improve returns on lower-ranked customers while also driving volume growth among higher-quality customers [53][54] Question: Condition of low-end consumers - Management indicated that while there are signs of strain on consumers, there are no significant cracks in the foundation yet, and the company remains a competitive option for financing [70][73] Question: Future direction of underwriting changes - Management is exploring opportunities to move upmarket while ensuring that core customers continue to have access to financing options [75][78] Question: Capital markets success and its impact - The company is focused on maturing its capital structure and has successfully securitized over $2 billion in receivables, which is expected to lower interest rates and fuel growth [82][84]

Company introduces breakthrough ad tools that deliver brand messages based on real-world behavior and prove in-store impact with deterministic measurementSAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- Life360 (Nasdaq: LIF), the leading family connection and safety company, today announced two category-defining innovations within its ad platform: Place Ads by Life360, a location-based, targeting product that reaches families based on real-world behavior and household context, and Uplift by Life360, a best- ...

Omer, Israel, June 12, 2025 (GLOBE NEWSWIRE) -- Odysight.ai Inc. (Nasdaq: ODYS), a leading provider of visual based predictive maintenance (PdM) and condition-based monitoring (CBM) solutions, today announced it will participate in the 15th Annual ROTH London Conference taking place June 25–26, 2025, in London, U.K. Einav Brenner, Chief Financial Officer, will be available for one-on-one investor meetings on site both days. To schedule a meeting, please contact your ROTH representative. About the ROTH Londo ...

Core Insights - Predictive Oncology Inc. has developed 3D organoid models for Labcorp to enhance drug discovery and preclinical analysis of cancer therapies [1][2][3] - The new models include human and rat liver toxicity models that simulate the liver microenvironment for evaluating drug metabolism and toxicity [2][3] - These organoid models aim to predict in vivo drug clearance, transport, and hepatotoxicity, providing species-specific data that captures hepatic cellular heterogeneity [3][4] Company Developments - The 3D organoid models complement Predictive Oncology's existing AI-driven 2D platform and 3D spheroids, which utilize a biobank of over 150,000 frozen tumor samples [3][6] - The company’s AI platform, PEDAL, predicts with 92% accuracy whether a tumor sample will respond to specific drug compounds, aiding in informed drug selection [6] Industry Trends - The use of organoid-based platforms is seen as a key driver in transforming healthcare, accelerating drug development, and reducing reliance on animal models [4] - There is a growing investment in personalized medicine and biotechnology, with organoids offering cost-effective and high-fidelity alternatives to traditional research methods [4]

Core Viewpoint - Intensity Therapeutics, Inc. has announced a public offering of 6,675,000 shares at a price of $0.30 per share, aiming to raise approximately $2,002,500 before expenses, with a closing date expected on June 13, 2025 [1][2] Group 1: Offering Details - The public offering consists of 6,675,000 shares priced at $0.30 each, generating gross proceeds of $2,002,500 [1] - The underwriters have a 45-day option to purchase an additional 1,001,250 shares to cover over-allotments [1] - The offering will close on June 13, 2025, pending customary closing conditions [1] Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for patient enrollment and data readout in the INVINCIBLE-4 Study, treatment of patients in the INVINCIBLE-3 Study, and for general corporate purposes [2] Group 3: Company Overview - Intensity Therapeutics is a late-stage clinical biotechnology company focused on developing immune-based intratumoral cancer therapies [5] - The investigational drug INT230-6 has shown potential in killing tumors and eliciting immune responses, with over 200 patients enrolled in clinical trials [5] - The company has completed two clinical studies and initiated a Phase 3 trial in soft tissue sarcoma and a Phase 2 study for presurgical triple-negative breast cancer [5]